(CercleFinance.com) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the United States Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (RP), a rare condition that affects 5-8% of children and adolescents with chronic inflammatory arthritis.
Two of Stelara’s four indications now include pediatric patients, further expanding its treatment profile since first approval in 2009 for adults affected by moderate to severe plaque psoriasis (PsO).
“With this pediatric approval of Stelara, we are excited to help address the unmet needs of these young patients and provide physicians with a much-needed treatment option that is proven to be safe and effective,” said reacted Terence Rooney, vice president in charge of rheumatology and fetomaternal diseases at Janssen Research & Development.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
